# A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma

Source: https://onco.cc/trials/nct06564272/  
OnCo record `nct06564272` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of KC1036 in ewing sarcoma, run by Beijing Konruns Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma is a phase 2 interventional study registered as NCT06564272 by Beijing Konruns Pharmaceutical Co., Ltd., with 30 participants planned, started 2024-09-27 and due to reach its primary completion in 2027-04-01. Interventions recorded: KC1036. Conditions listed: Ewing Sarcoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06564272
- Phase: 2
- Setting: A Phase II Study to Evaluate the Safety and Efficacy of KC1036 in Adolescents Aged 12 and Above With Advanced Ewing Sarcoma
- Sponsor: Beijing Konruns Pharmaceutical Co., Ltd.
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT06564272: https://clinicaltrials.gov/study/NCT06564272

## Connected records

- cancers: [Ewing sarcoma](https://onco.cc/cancers/ewing-sarcoma/)
- drugs: [KC1036](https://onco.cc/drugs/kc1036/)
- companies: [Beijing Konruns Pharmaceutical](https://onco.cc/companies/beijing-konruns-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct06564272.json